Targeting two cancer cell defenses may offer new treatment strategy

Cancer cells must protect themselves from the harmful substances they produce as they grow. Now, researchers have identified how they neutralize one of these substances, formaldehyde, while keeping another defence against cell death intact. The findings suggest a way to attack both defenses together, and the next step is to find out whether it could become a treatment.

Formaldehyde is produced naturally inside cells and can damage DNA by binding it to nearby proteins. Cells neutralize it using glutathione, a molecule that protects against chemical damage. Glutathione also prevents ferroptosis, a form of cell death caused by damage to fats in the cell membrane. Both tasks depend on the same supply of glutathione, so using it to deal with formaldehyde can leave less available for the other task. The study explains how cancer cells can maintain both defences.

The research, led by Lucas Pontel's group at the Josep Carreras Leukaemia Research Institute, focused on a protein called NRF2. Often overactive in tumours, NRF2 controls a process that helps cancer cells neutralise formaldehyde while preserving their glutathione supply.

How cancer cells preserve their defenses

NRF2 increases production of SLC7A11, a protein that transports a molecule called cystine into cells. Once inside, cystine is converted into cysteine, which can react directly with formaldehyde without using glutathione. This reaction produces a stable compound called thioproline, which the researchers detected in cancer cells. By taking in more cystine, the cells can deal with formaldehyde and keep glutathione available to prevent ferroptosis.

Blocking both defenses

Blocking SLC7A11 in cells exposed to high levels of formaldehyde stopped protein production and triggered cell death. The researchers also used drugs to block both cystine uptake and glutathione production. This combination killed leukemia cells, as well as various types of solid tumors such as lung and colon cancers and brain tumor cells.

What this could mean for leukemia

The results suggest that targeting both defenses could be worth investigating as a treatment approach for leukemia. In patients with myeloid leukemia, higher levels of SLC7A11 are associated with poorer survival. This raises the possibility that these cancers depend on the defense system identified in the study. The team now plans to investigate whether blocking it could lead to a safe and effective treatment.

The study also involved Dr Gael Roué's group at the Josep Carreras Institute and researchers from the University of Leicester (United Kingdom), the Institute of Biomedicine of Buenos Aires (IBioBA-MPSP, Argentina) and the International University of Catalonia (UIC).

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Broad genomic sequencing extends survival in advanced lung cancer patients